N@N

Market Maker Surveillance Report. DRYS, MBRX, EYES, PIP, RGSE, CXRX, Losing Stocks With Lowest Price Friction For Wednesday, F

February 8, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 5601 companies with "abnormal" market making, 3228 companies with positive Friction Factors and 2635 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. DryShips Inc. (NASDAQ:DRYS), Moleculin Biotech Inc. (NASDAQ:MBRX), Second Sight Medical Products (NASDAQ:EYES), PharmAthene, Inc. (NYSE:PIP), Real Goods Solar (NASDAQ:RGSE), Concordia Healthcare Corp (NASDAQ:CXRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  DRYS    $-0.840   -0.17%    8,342,982    34.00%    9,249,120    37.69%    -906,138     -10,787 
  MBRX    $-0.290   -0.16%    92,580       30.01%    113,360      36.75%    -20,780      -717    
  EYES    $-0.760   -0.28%    1,816,796    38.17%    2,006,360    42.16%    -189,564     -2,494  
  PIP     $-0.230   -0.17%    8,948,321    39.44%    9,004,637    39.69%    -56,316      -2,449  
  RGSE    $-0.650   -0.23%    1,462,196    37.34%    1,677,028    42.82%    -214,832     -3,305  
  CXRX    $-0.810   -0.23%    1,191,967    28.60%    1,548,325    37.15%    -356,358     -4,399  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows DRYS with a dollar loss Wednesday of $-0.84000 and a Friction Factor of -10,787 shares. That means that it only took 10,787 more shares of selling than buying to move DRYS lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

DryShips Inc. (NASDAQ:DRYS) - DryShips Inc. provides seaborne dry cargo and offshore support services. The company operates through Drybulk and Offshore Support segments. The Drybulk segment provides drybulk commodities transportation services for the steel, electric utility, construction, and agri-food industries. The Offshore Support segment offers its services to the global offshore energy industry. As of January 20, 2017, it owned a fleet of 13 Panamax drybulk carriers with a combined deadweight tonnage of approximately 1.0 million tons; and 6 offshore supply vessels comprising 2 platform supply and 4 oil spill recovery vessels, as well as 1 very large gas carrier newbuilding. The company was founded in 2004 and is based in Athens, Greece..

Moleculin Biotech Inc. (NASDAQ:MBRX) - Metabasis Therapeutics, Inc. (Metabasis), incorporated in April 1997, is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for chronic diseases involving pathways in the liver. The Company has four product candidates in clinical trials: Pradefovir, CS-917, MB07133 and MB07803. Pradefovir for the treatment of hepatitis B has completed Phase II clinical trials. CS-917 for the treatment of type 2 diabetes is in Phase II clinical trials. MB07133 for the treatment of primary liver cancer is in a Phase I/II clinical trial. MB07803, also for the treatment of type 2 diabetes, is in a Phase I clinical trial. Metabasis uses its HepDirect technology and other liver-targeting technology in collaboration with Merck & Co. to identify drugs to treat hepatitis C infection. The Company also uses NuMimetic technology in collaboration with Merck to treat metabolic diseases such as type 2 diabetes, hyperlipidemia and non-alcoholic steatohepatitis, by inhibiting cholesterol and lipid production in the liver.

Pradefovir

Pradefovir is an oral product candidate designed using the Company's HepDirect technology. It delivers high concentrations of adefovir to the liver, while limiting the amount of adefovir generated outside of the liver to reduce dose-related toxicities.

CS-917

CS-917, an oral product candidate for type 2 diabetes, inhibits a metabolic pathway in the liver called gluconeogenesis, which is responsible for the excessive production of glucose by patients with type 2 diabetes. The product is being developed in partnership with Daiichi Sankyo Co., Ltd., which has completed a number of Phase I clinical trials of CS-917 in healthy volunteers, as well as Phase I and Phase II clinical trials of CS-917 in type 2 diabetic patients. In February 2006, a Phase IIb clinical trial of CS-917 was initiated by Daiichi Sankyo.

MB07133

MB07133 is an intravenously administered product candidate in a Phase I/II clinical trial designed to evaluate safety and preliminary efficacy in a limited number of patients with primary liver cancer. Using the HepDirect technology, the product targets the active form of araC to the liver while decreasing levels of the active form of the drug in tissues outside of the liver.

MB07803

MB07803 is an oral product candidate for type 2 diabetes that was discovered using Metabasis' NuMimetic technology. Designed to have the same mechanism of action as CS-917, the second-generation drug blocks the gluconeogenesis pathway in the liver by inhibiting FBPase.

MB07811

Metabasis has a clinical development candidate, MB07811, for the treatment of high cholesterol and obesity. MB07811 is designed to act by controlling the expression of certain genes in the liver. The product is undergoing pre-clinical development including scale-up, toxicology (animal studies) and formulations development..

Second Sight Medical Products (NASDAQ:EYES) - Second Sight Medical Products, Inc. develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the United States, Canada, Italy, France, Germany, Saudi Arabia, and the Netherlands. It offers Argus II System, an implantable neurostimulation device that uses electrical stimulation of the retina to replace the function of the defunct photo-receptors in retinitis pigmentosa patients. The company sells its Argus II System to university hospitals, large medical centers, and distributors. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California..

PharmAthene, Inc. (NYSE:PIP) - PharmAthene, Inc., a biodefense company, develops and commercializes medical counter measures against biological and chemical threats in the United States. The company focuses on developing lyophilized anthrax vaccines based on DepoVax, a proprietary technology platform that contributes recombinant protective antigen bulk drug substance. It serves National Institute of Allergy and Infectious Diseases, and the Biomedical Advanced Research and Development Authority. The company has a license agreement with ImmunoVaccine Technologies for the use of the DepoVax vaccine platform to develop an anthrax vaccine. PharmAthene, Inc. is headquartered in Annapolis, Maryland..

Real Goods Solar (NASDAQ:RGSE) - .

Concordia Healthcare Corp (NASDAQ:CXRX) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---